GILD – Gilead Sciences, Inc.
GILD — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
1.61
Margin Of Safety %
-5
Put/Call OI Ratio
0.52
EPS Next Q Diff
0.24
EPS Last/This Y
1.84
EPS This/Next Y
0.93
Price
134.21
Target Price
159.96
Analyst Recom
1.66
Performance Q
6.83
Upside
11.1%
Beta
0.42
Ticker: GILD
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-02-27 | GILD | 149.02 | 0.71 | 0.50 | 157573 |
| 2026-03-02 | GILD | 150.06 | 0.69 | 0.34 | 152835 |
| 2026-03-03 | GILD | 147.83 | 0.67 | 0.60 | 157478 |
| 2026-03-04 | GILD | 148.25 | 0.67 | 4.57 | 157957 |
| 2026-03-05 | GILD | 145.13 | 0.66 | 0.40 | 158253 |
| 2026-03-06 | GILD | 143.91 | 0.66 | 0.85 | 159237 |
| 2026-03-09 | GILD | 146.65 | 0.67 | 0.52 | 156046 |
| 2026-03-10 | GILD | 148.44 | 0.67 | 0.29 | 157933 |
| 2026-03-11 | GILD | 145.95 | 0.66 | 0.45 | 160397 |
| 2026-03-12 | GILD | 145.22 | 0.66 | 0.02 | 164198 |
| 2026-03-13 | GILD | 145.21 | 0.66 | 0.02 | 164198 |
| 2026-03-17 | GILD | 144.44 | 0.73 | 1.57 | 159091 |
| 2026-03-18 | GILD | 141.3 | 0.73 | 0.64 | 160245 |
| 2026-03-19 | GILD | 140.81 | 0.74 | 0.86 | 161072 |
| 2026-03-20 | GILD | 137.17 | 0.73 | 1.63 | 160926 |
| 2026-03-23 | GILD | 137.34 | 0.59 | 0.83 | 127349 |
| 2026-03-24 | GILD | 138.1 | 0.60 | 0.48 | 130944 |
| 2026-03-25 | GILD | 138.27 | 0.61 | 0.48 | 131654 |
| 2026-03-26 | GILD | 136.89 | 0.60 | 0.14 | 133292 |
| 2026-03-27 | GILD | 134.22 | 0.52 | 0.19 | 147446 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-02-27 | GILD | 148.95 | 5.1 | 7110.8 | 8.68 |
| 2026-03-02 | GILD | 150.01 | 5.1 | 1809.9 | 8.68 |
| 2026-03-03 | GILD | 147.83 | 5.1 | 1557.5 | 8.68 |
| 2026-03-04 | GILD | 148.23 | 5.1 | 1758.8 | 8.68 |
| 2026-03-05 | GILD | 145.13 | 5.3 | 1486.3 | 8.68 |
| 2026-03-06 | GILD | 143.98 | 5.3 | 1635.3 | 8.68 |
| 2026-03-09 | GILD | 146.64 | 5.3 | 1945.0 | 8.68 |
| 2026-03-10 | GILD | 148.60 | 5.3 | 1883.4 | 8.68 |
| 2026-03-11 | GILD | 145.99 | 5.3 | 1527.0 | 8.68 |
| 2026-03-12 | GILD | 145.21 | 5.3 | 1664.9 | 8.68 |
| 2026-03-13 | GILD | 144.98 | 5.3 | 1709.2 | 8.68 |
| 2026-03-17 | GILD | 144.41 | 5.7 | 1663.8 | 8.68 |
| 2026-03-18 | GILD | 141.30 | 5.7 | 1479.3 | 8.68 |
| 2026-03-19 | GILD | 141.06 | 5.7 | -1784.1 | 8.68 |
| 2026-03-20 | GILD | 137.21 | 5.4 | -2000.5 | 8.68 |
| 2026-03-23 | GILD | 137.35 | 5.4 | -1761.8 | 8.68 |
| 2026-03-24 | GILD | 138.10 | 5.4 | -1724.6 | 8.68 |
| 2026-03-25 | GILD | 138.26 | 5.4 | -1761.8 | 8.68 |
| 2026-03-26 | GILD | 136.91 | 5.4 | -1849.2 | 8.68 |
| 2026-03-27 | GILD | 134.21 | 5.4 | -1920.8 | 8.68 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-02-27 | GILD | -23.00 | 0.61 | 1.77 |
| 2026-03-02 | GILD | -23.00 | 1.26 | 1.77 |
| 2026-03-03 | GILD | -23.00 | 1.26 | 1.77 |
| 2026-03-04 | GILD | -23.00 | 1.26 | 1.77 |
| 2026-03-05 | GILD | -23.00 | 1.26 | 1.77 |
| 2026-03-06 | GILD | -23.00 | 1.26 | 1.77 |
| 2026-03-09 | GILD | -23.00 | 1.22 | 1.77 |
| 2026-03-10 | GILD | -23.00 | 1.22 | 1.77 |
| 2026-03-11 | GILD | -23.00 | 1.22 | 1.49 |
| 2026-03-12 | GILD | -23.00 | 1.22 | 1.49 |
| 2026-03-13 | GILD | -23.00 | 1.22 | 1.49 |
| 2026-03-17 | GILD | -22.90 | 1.26 | 1.49 |
| 2026-03-18 | GILD | -23.02 | 1.26 | 1.49 |
| 2026-03-19 | GILD | -23.02 | 1.26 | 1.49 |
| 2026-03-20 | GILD | -23.02 | 1.26 | 1.49 |
| 2026-03-23 | GILD | -23.02 | 1.22 | 1.49 |
| 2026-03-24 | GILD | -23.02 | 1.22 | 1.49 |
| 2026-03-25 | GILD | -23.02 | 1.22 | 1.61 |
| 2026-03-26 | GILD | -23.02 | 1.22 | 1.61 |
| 2026-03-27 | GILD | -23.02 | 1.22 | 1.61 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
1.86
Avg. EPS Est. Current Quarter
1.91
Avg. EPS Est. Next Quarter
2.1
Insider Transactions
-23.02
Institutional Transactions
1.22
Beta
0.42
Average Sales Estimate Current Quarter
6923
Average Sales Estimate Next Quarter
7406
Fair Value
127.27
Quality Score
95
Growth Score
78
Sentiment Score
71
Actual DrawDown %
14.7
Max Drawdown 5-Year %
-26.6
Target Price
159.96
P/E
19.79
Forward P/E
13.89
PEG
1.57
P/S
5.66
P/B
7.34
P/Free Cash Flow
17.62
EPS
6.78
Average EPS Est. Cur. Y
8.68
EPS Next Y. (Est.)
9.61
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
28.9
Relative Volume
0.79
Return on Equity vs Sector %
10.1
Return on Equity vs Industry %
0.8
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.03
EBIT Estimation
-1920.8
◆
GILD
Healthcare
$134.25
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
32
Range 1M
0.1%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
6.5%
EPS NY
11.4%
52W%
64.9%
Long-Term Value
Quality companies, undervalued
WATCH
🟢 BUY
+31% upside
Upside
+31%
Quality
95
MoS
-5%
Gilead Sciences, Inc.Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 17000
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
GILD
Latest News
—
Caricamento notizie per GILD…
stock quote shares GILD – Gilead Sciences, Inc. Stock Price stock today
news today GILD – Gilead Sciences, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch GILD – Gilead Sciences, Inc. yahoo finance google finance
stock history GILD – Gilead Sciences, Inc. invest stock market
stock prices GILD premarket after hours
ticker GILD fair value insiders trading